[go: up one dir, main page]

WO2008156644A3 - Stat modulators - Google Patents

Stat modulators Download PDF

Info

Publication number
WO2008156644A3
WO2008156644A3 PCT/US2008/007349 US2008007349W WO2008156644A3 WO 2008156644 A3 WO2008156644 A3 WO 2008156644A3 US 2008007349 W US2008007349 W US 2008007349W WO 2008156644 A3 WO2008156644 A3 WO 2008156644A3
Authority
WO
WIPO (PCT)
Prior art keywords
stat
compounds
useful
present
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/007349
Other languages
French (fr)
Other versions
WO2008156644A2 (en
Inventor
David A Frank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2008156644A2 publication Critical patent/WO2008156644A2/en
Publication of WO2008156644A3 publication Critical patent/WO2008156644A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention is directed to methods, kits and compositions for modulating the activity of Stat molecules (e.g., Statl, Stat3 and Stat5). The compounds of the invention are useful for treating and/or preventing disorders characterized by Stat dysregulation, such as hyperproliferative disorders. Further, the compounds of the present invention are also useful in culturing stem cells and treating ischemic disorders.
PCT/US2008/007349 2007-06-14 2008-06-12 Stat modulators Ceased WO2008156644A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93453507P 2007-06-14 2007-06-14
US60/934,535 2007-06-14

Publications (2)

Publication Number Publication Date
WO2008156644A2 WO2008156644A2 (en) 2008-12-24
WO2008156644A3 true WO2008156644A3 (en) 2009-02-19

Family

ID=40156842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/007349 Ceased WO2008156644A2 (en) 2007-06-14 2008-06-12 Stat modulators

Country Status (1)

Country Link
WO (1) WO2008156644A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2723892A2 (en) 2011-06-27 2014-04-30 Galderma Research & Development New th-17 differentiation markers for rosacea and uses thereof
EP2723893B1 (en) 2011-06-27 2018-11-21 Galderma Research & Development New th-17 differentiation markers for rosacea and uses thereof
WO2013000869A1 (en) 2011-06-27 2013-01-03 Galderma Research & Development New th17 differentiation markers for acne and uses thereof
WO2013000870A1 (en) 2011-06-27 2013-01-03 Galderma Research & Development New th17 differentiation markers for acne and uses thereof
BR112015002626A2 (en) * 2012-11-29 2017-09-26 Yeda Res & Dev methods for tumor metastasis prevention, cancer treatment and prognosis, and identification of agents that are putative metastasis inhibitors
JP2017031059A (en) * 2014-01-29 2017-02-09 学校法人慶應義塾 Cancer stem cell growth inhibitor and intracellular active oxygen accumulation inducer
CN104398517A (en) * 2014-11-28 2015-03-11 四川大学 New application of pyrimethamine and medicinal composition for treating for tumor
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
SG11202101093QA (en) * 2018-08-24 2021-04-29 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
JP7492752B2 (en) * 2018-10-23 2024-05-30 ウニベルシテ カソリーク デ ルーベン Guanabenz as an adjuvant for immunotherapy
CN109793729A (en) * 2019-02-27 2019-05-24 四川大学华西医院 Use of nifurazide or its salt in the treatment of osteosarcoma
CN113939300A (en) 2019-04-05 2022-01-14 凯麦拉医疗公司 STAT degradants and uses thereof
WO2020216335A1 (en) * 2019-04-26 2020-10-29 健艾仕生物医药有限公司 Use of compound in preparation of drug for treating atherosclerosis
BR112022000254A2 (en) * 2019-07-08 2022-03-15 Edward Keefer Use of immune modulators to improve nerve regeneration
WO2021214129A1 (en) 2020-04-21 2021-10-28 Université Catholique de Louvain Alpha-2 adrenergic receptor agonists for the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040010001A1 (en) * 1999-06-03 2004-01-15 Au Jessie L.-S. Methods and compositions for modulating cell proliferation and cell death
US20040063769A1 (en) * 2001-01-24 2004-04-01 Alexis Borisy Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
US20070031871A1 (en) * 2005-07-20 2007-02-08 University Of South Florida Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040010001A1 (en) * 1999-06-03 2004-01-15 Au Jessie L.-S. Methods and compositions for modulating cell proliferation and cell death
US20040063769A1 (en) * 2001-01-24 2004-04-01 Alexis Borisy Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
US20070031871A1 (en) * 2005-07-20 2007-02-08 University Of South Florida Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments

Also Published As

Publication number Publication date
WO2008156644A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
WO2008156644A3 (en) Stat modulators
WO2007115315A3 (en) Pyrrolo- and thiazolo-pyridine compounds as hif modulators
MX2010005648A (en) Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators.
ATE513833T1 (en) THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
MY153057A (en) Tryclic compounds,compositions and methods
WO2007002718A3 (en) Rnai modulation of hif-1 and theraputic uses thereof
EA201100378A1 (en) HEDGEHOG SIGNAL MODULATORS
WO2008061236A3 (en) Sulfoximines as kinase inhibitors
AU2009319796A8 (en) Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockers
NZ624460A (en) Process for making modulators of cystic fibrosis transmembrane conductance regulator
ATE543854T1 (en) NEW POLYCARBONATE-POLYORGANOSILOXANE AND/OR POLYURETHANE-POLYORGANOSILOXANE COMPOUNDS
WO2010138820A3 (en) N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
EP4585589A3 (en) Stem cell cultures
WO2009100294A3 (en) Amide derivatives as positive allosteric modulators and methods of use thereof
NO20074002L (en) Androgen receptor modulator compounds and methods
WO2008130953A3 (en) 2-imin0is0thiaz0le derivatives as cannabinoid receptor ligands
MX2009012374A (en) Novel compounds as cannabinoid receptor ligands.
WO2008032227A3 (en) Topical formulations of tellurium-containing compounds
WO2007053765A3 (en) Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
WO2007056143A3 (en) Certain chemical entities, compositions, and methods
DE502006005290D1 (en) LOW VISCOSIS OF URETDION GROUPP-BASED POLYADDITION COMPOUNDS, METHOD OF PREPARATION AND USE
MX339840B (en) Modulators of 5-ht receptors and methods of use thereof.
WO2009037542A3 (en) Spirocyclic compounds as stearoyl coa desaturase inhibitors
WO2008090417A3 (en) Inhibition of nf-kb
WO2007056469A3 (en) Certain chemical entities, compositions, and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08768396

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08768396

Country of ref document: EP

Kind code of ref document: A2